Revolution Medicines' Pancreatic Cancer Pill Doubles Survival as Germany Launches New Oncology Nursing Service

A experimental pill called Daraxonrasib (branded Daraxon) from US biotech firm Revolution Medicines has shown a remarkable result in pancreatic cancer trials, extending patient survival to an average of 13 months—about twice the length of standard chemotherapy. The company disclosed the data in April and plans to present full details at the American Society of Clinical Oncology meeting in Chicago. German regulators have already broadened access to the drug while its approval is under review. "Das ist der Beginn einer riesigen Welle für diese Krankheit," said gastro‑intestinal oncologist Eileen O’Reilly.

In Leipzig, the University Cancer Center (UCCL) opened a new oncology nursing counseling service, OPAL, on 1 June. The programme offers dedicated advice on medication, side‑effects, nutrition and everyday support for cancer patients and their families, with specially trained nurses providing personalized guidance in both inpatient and outpatient settings. Director Prof. Florian Lordick and senior staff highlighted the importance of nursing expertise in improving patient care.

Both developments aim to enhance outcomes for German cancer patients, one through a breakthrough drug targeting the KRAS protein in pancreatic tumors, the other by strengthening supportive care during treatment.